AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14617058 — intervention group
Group type: COMPARATOR
Intervention: Programme without ankle disc (functional strength training only)
Number of subjects: 16
Study 14617058 — intervention group
Group type: EXPERIMENTAL
Intervention: Programme with ankle disc
Number of subjects: 16
Study 10518002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of 3.5 times the RDI of folic acid and B12
Number of subjects: 0
Study 10518002 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine (HC) below 7.5 micromol/l
Number of subjects: 0
Study 10518002 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vitamin B12 (B12) above 300 pmol/l
Number of subjects: 0
Study 8523035 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS serum levels in HC subjects
Number of subjects: 11
Study 8523035 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT levels in HC subjects
Number of subjects: 11
Study 8523035 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS/CRT ratio in HC subjects
Number of subjects: 11
Study 8523035 — intervention group
Group type: COMPARATOR
Intervention: DHEAS serum levels in normal controls
Number of subjects: 11
Study 8523035 — intervention group
Group type: COMPARATOR
Intervention: CRT levels in normal controls
Number of subjects: 11
Study 8523035 — intervention group
Group type: COMPARATOR
Intervention: DHEAS/CRT ratio in normal controls
Number of subjects: 11
Study 1646066 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) and cisplatin (C)
Number of subjects: 247
Study 1646066 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU, C, and vinblastine (V)
Number of subjects: 247
Study 1646066 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status 0 or 1
Number of subjects: 247
Study 1646066 — intervention group
Group type: COMPARATOR
Intervention: Performance status 2 or greater
Number of subjects: 247
Study 1646066 — intervention group
Group type: COMPARATOR
Intervention: Prior locoregional radiation therapy
Number of subjects: 247
Study 1646066 — intervention group
Group type: COMPARATOR
Intervention: Performance status
Number of subjects: 247
Study 1646066 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU, C, and V
Number of subjects: 247
Study 1646066 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU plus C
Number of subjects: 247
Study 6275776 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 6
Study 6275776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 6
Study 6275776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 6
Study 6275776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime with probenecid
Number of subjects: 6
Study 6275776 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam and ceftazidime
Number of subjects: 6
Study 30450601 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombosomes
Number of subjects: 15
Study 30450601 — intervention group
Group type: COMPARATOR
Intervention: Control (buffer solution)
Number of subjects: 15
Study 27756351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hockey FIT (12-week Active Phase and 40-week Maintenance Phase)
Number of subjects: 80
Study 27756351 — intervention group
Group type: COMPARATOR
Intervention: Wait-List Control
Number of subjects: 80
Study 25536254 — intervention group
Group type: COMPARATOR
Intervention: 33.5°C for 72 hours
Number of subjects: 364
Study 25536254 — intervention group
Group type: EXPERIMENTAL
Intervention: 32.0°C for 72 hours
Number of subjects: 364
Study 25536254 — intervention group
Group type: EXPERIMENTAL
Intervention: 33.5°C for 120 hours
Number of subjects: 364
Study 25536254 — intervention group
Group type: EXPERIMENTAL
Intervention: 32.0°C for 120 hours
Number of subjects: 364
Study 25536254 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 hours group
Number of subjects: 364
Study 25536254 — intervention group
Group type: EXPERIMENTAL
Intervention: 32.0°C group
Number of subjects: 364
Study 25536254 — intervention group
Group type: COMPARATOR
Intervention: 72 hours group
Number of subjects: 364
Study 25536254 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer cooling, deeper cooling, or both
Number of subjects: 364
Study 23032205 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) with hybrid light (HL)
Number of subjects: 48
Study 23032205 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP)
Number of subjects: 48
Study 23032205 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% hydrogen peroxide (HP) with hybrid light (HL)
Number of subjects: 48
Study 23032205 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% hydrogen peroxide (HP)
Number of subjects: 48
Study 23032205 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide (CP)
Number of subjects: 48
Study 21291031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual ketorolac (30 mg/1 mL) and mepivacaine paracervical block
Number of subjects: 40
Study 21291031 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine-only paracervical injection (standard group)
Number of subjects: 40
Study 18558641 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin A
Number of subjects: 4345
Study 18558641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4345
Study 16114163 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes care and management in private clinics
Number of subjects: 438
Study 11803342 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical tracheostomy (ST)
Number of subjects: 50
Study 11803342 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 50
Study 11803342 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 50
Study 10023614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive outpatient or short-term residential treatment
Number of subjects: 21
Study 7587740 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human macrophage colony-stimulating factor (rhM-CSF)
Number of subjects: 0
Study 7587740 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)
Number of subjects: 0
Study 7587740 — intervention group
Group type: COMPARATOR
Intervention: rhM-CSF
Number of subjects: 0
Study 1690374 — intervention group
Group type: EXPERIMENTAL
Intervention: CSM
Number of subjects: 42
Study 1690374 — intervention group
Group type: COMPARATOR
Intervention: CSM-dextran
Number of subjects: 42
Study 7188827 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free (LF) chocolate dairy drink
Number of subjects: 87
Study 7188827 — intervention group
Group type: COMPARATOR
Intervention: Lactose-containing (LC) dairy drink (4.5% lactose)
Number of subjects: 87
Study 7052000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside at the rate of 2 microgram per kilogram per minute during the payback period
Number of subjects: 38
Study 7052000 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water (D5W)
Number of subjects: 38
Study 7052000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 38
Study 7052000 — intervention group
Group type: COMPARATOR
Intervention: D5W
Number of subjects: 38
Study 31128953 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone game intervention
Number of subjects: 36
Study 31128953 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline lifestyle counseling)
Number of subjects: 36
Study 31128953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 27989255 — intervention group
Group type: EXPERIMENTAL
Intervention: Filmed social contact (FSC)
Number of subjects: 259
Study 27989255 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional Internet search (INS)
Number of subjects: 259
Study 27989255 — intervention group
Group type: COMPARATOR
Intervention: Control (PC games)
Number of subjects: 259
Study 26799632 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg BI 135585 (single dose)
Number of subjects: 0
Study 26799632 — intervention group
Group type: COMPARATOR
Intervention: 5-200 mg BI 135585 (multiple doses)
Number of subjects: 0
Study 25377907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 0
Study 25377907 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0
Study 22722509 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (AGO) 25-50 mg/d
Number of subjects: 60
Study 22722509 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR (VLX) 75-150 mg/d
Number of subjects: 60
Study 20101013 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month multipurpose exercise program with special emphasis on exercise intensity (n = 123)
Number of subjects: 246
Study 20101013 — intervention group
Group type: COMPARATOR
Intervention: Wellness program (control group, n = 123)
Number of subjects: 246
Study 20101013 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month multipurpose exercise program
Number of subjects: 246
Study 20101013 — intervention group
Group type: COMPARATOR
Intervention: Wellness program (control group)
Number of subjects: 246
Study 20101013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year CHD risk for exercise group
Number of subjects: 246
Study 20101013 — intervention group
Group type: COMPARATOR
Intervention: 10-year CHD risk for control group
Number of subjects: 246
Study 20101013 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct health care costs per participant during the 18-month intervention for exercise group
Number of subjects: 246
Study 20101013 — intervention group
Group type: COMPARATOR
Intervention: Direct health care costs per participant during the 18-month intervention for control group
Number of subjects: 246
Study 17598865 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly PUVA
Number of subjects: 28
Study 17598865 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly PUVA
Number of subjects: 28
Study 16236163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal lavage fluid from patients with allergic rhinitis
Number of subjects: 22
Study 16236163 — intervention group
Group type: COMPARATOR
Intervention: Nasal lavage fluid from healthy volunteers
Number of subjects: 22
Study 12236845 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated beads (1 x 200 mg)
Number of subjects: 18
Study 12236845 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated mini-tablets (4 x 50 mg)
Number of subjects: 18
Study 12236845 — intervention group
Group type: COMPARATOR
Intervention: Buffered tablet (2 x 100 mg)
Number of subjects: 18
Study 11341606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg bd for five days presurgery
Number of subjects: 72
Study 11341606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7488278 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg cM-T412
Number of subjects: 64
Study 7488278 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cM-T412
Number of subjects: 64
Study 7488278 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg cM-T412
Number of subjects: 64
Study 7488278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 2302375 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and fentanyl combination
Number of subjects: 60
Study 2302375 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl alone
Number of subjects: 60
Study 2302375 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 60
Study 7435246 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (15 g/day)
Number of subjects: 0
Study 7435246 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no medication
Number of subjects: 0
Study 30387500 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative version of toolbox talks
Number of subjects: 0
Study 30387500 — intervention group
Group type: COMPARATOR
Intervention: Standard version of toolbox talks
Number of subjects: 0
Study 27491293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-CBT
Number of subjects: 19
Study 26298832 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of vaporized cannabis (22 mg THC)
Number of subjects: 55
Study 26298832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of vaporized cannabis (5.5 mg THC)
Number of subjects: 55
Study 26298832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 23954406 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted sleep (5.5-h time-in-bed)
Number of subjects: 11
Study 23954406 — intervention group
Group type: COMPARATOR
Intervention: Adequate sleep (8.5-h time-in-bed)
Number of subjects: 11
Study 21138496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitadur‐N‐veneered crowns
Number of subjects: 40
Study 21138496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitadur‐α‐veneered crowns
Number of subjects: 40
Study 21138496 — intervention group
Group type: EXPERIMENTAL
Intervention: VM7‐veneered crowns
Number of subjects: 40
Study 21138496 — intervention group
Group type: COMPARATOR
Intervention: Alumina cores (unveneered)
Number of subjects: 40
Study 18372467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade glioma patients (transformers)
Number of subjects: 13
Study 18372467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade glioma patients (nontransformers)
Number of subjects: 13
Study 18372467 — intervention group
Group type: COMPARATOR
Intervention: Comparison of rCBV changes between transformers and nontransformers
Number of subjects: 13
Study 16630017 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot chlorination
Number of subjects: 127
Study 16630017 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 127
Study 12618744 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) as initial long-term control therapy
Number of subjects: 0
Study 12618744 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11112027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (tacrolimus/corticosteroids)
Number of subjects: 491
Study 11112027 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (tacrolimus/corticosteroids/azathioprine)
Number of subjects: 491
Study 9493932 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental foam surface
Number of subjects: 10
Study 9493932 — intervention group
Group type: COMPARATOR
Intervention: Standard innerspring mattress
Number of subjects: 10
Study 8323890 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg plain bupivacaine (isobaric group)
Number of subjects: 65
Study 8323890 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine (hyperbaric group)
Number of subjects: 65
Study 8323890 — intervention group
Group type: COMPARATOR
Intervention: Both groups (isobaric and hyperbaric)
Number of subjects: 65
Study 3737634 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 25 mg
Number of subjects: 20
Study 3737634 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) 75 mg
Number of subjects: 20
Study 3737634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (MAZ) 0.5 mg
Number of subjects: 20
Study 3737634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (MAZ) 2.0 mg
Number of subjects: 20
Study 3737634 — intervention group
Group type: COMPARATOR
Intervention: D-amphetamine (AMP) 10 mg
Number of subjects: 20
Study 29388417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne distraction osteogenesis (DO); activated twice daily by a total amount of 0.5 mm per day for 3 weeks after a 7-day latency period.
Number of subjects: 21
Study 29388417 — intervention group
Group type: COMPARATOR
Intervention: Conventional Le Fort 1 osteotomy; pre and postsurgery lateral cephalograms obtained.
Number of subjects: 21
Study 26086397 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing the orientation re-enactment DVD prior to placement
Number of subjects: 47
Study 26086397 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not view the DVD)
Number of subjects: 47
Study 26048054 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation training
Number of subjects: 0
Study 26048054 — intervention group
Group type: COMPARATOR
Intervention: Traditional balance training
Number of subjects: 0
Study 23835824 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced practice approach using AIM-HI tools
Number of subjects: 610
Study 23835824 — intervention group
Group type: COMPARATOR
Intervention: Traditional practice approach using AIM-HI tools
Number of subjects: 610
Study 20675956 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 20675956 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II-receptor blockers (ARBs)
Number of subjects: 0
Study 20675956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual blockade of the renin-angiotensin system (RAS)
Number of subjects: 0
Study 20675956 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors or ARBs
Number of subjects: 0
Study 18436085 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary counseling with regular follow-up (aimed at achieving an intake of 0.8 to 1.0 g/kg of protein and greater than 125 kJ/kg of energy)
Number of subjects: 56
Study 18436085 — intervention group
Group type: COMPARATOR
Intervention: Written material only (control)
Number of subjects: 56
Study 17283863 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine 8‐16 mg/day
Number of subjects: 108
Study 17283863 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 2.5‐5 mg/day
Number of subjects: 108
Study 12805334 — intervention group
Group type: COMPARATOR
Intervention: Arsenic trioxide (ATO) alone
Number of subjects: 20
Study 12805334 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) plus all-trans-retinoic acid (ATRA)
Number of subjects: 20
Study 10805607 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR (Progynova TS, transdermal estradiol; n=19)
Number of subjects: 37
Study 10805607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 37
Study 8793308 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential relapse prevention/health education treatment
Number of subjects: 140
Study 1451289 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fish oil (FO) applied daily for 6 hours under an occlusive dressing for 4 weeks
Number of subjects: 25
Study 1451289 — intervention group
Group type: COMPARATOR
Intervention: Liquid paraffin (LP) applied daily for 6 hours under an occlusive dressing for 4 weeks
Number of subjects: 25
Study 1451289 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fish oil (FO)
Number of subjects: 25
Study 6362961 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 0
Study 31246895 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 4011
Study 31246895 — intervention group
Group type: COMPARATOR
Intervention: No glyceryl trinitrate
Number of subjects: 4011
Study 29902305 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-nicotine-content cigarettes (VLNCCs)
Number of subjects: 238
Study 29902305 — intervention group
Group type: COMPARATOR
Intervention: Normal-nicotine-content cigarettes (NNCCs)
Number of subjects: 238
Study 26907502 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii-based Movement Therapy (WMT)
Number of subjects: 46
Study 26907502 — intervention group
Group type: COMPARATOR
Intervention: modified Constraint‐induced Movement Therapy (mCIMT)
Number of subjects: 46
Study 23130813 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative evaluation/social rejection
Number of subjects: 74
Study 23130813 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative evaluation/academic (writing)
Number of subjects: 74
Study 22770852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined femoral nerve block and sciatic nerve block (FNB-SNB)
Number of subjects: 52
Study 22770852 — intervention group
Group type: COMPARATOR
Intervention: Combined femoral nerve block and periarticular infiltration (FNB-PI)
Number of subjects: 52
Study 19852905 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with comorbidities (suicidality and/or substance use)
Number of subjects: 498
Study 19852905 — intervention group
Group type: COMPARATOR
Intervention: Patients without comorbidities
Number of subjects: 498
Study 17852084 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB-UVB) radiation
Number of subjects: 50
Study 17852084 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic photochemotherapy (psoralen plus UVA - PUVA)
Number of subjects: 50
Study 17852084 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 16208658 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary job-retention vocational rehabilitation program (n = 74)
Number of subjects: 140
Study 16208658 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient care (n = 66)
Number of subjects: 140
Study 12432015 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT; 20x 30 min sessions of voluntary normocapnic hyperpnea)
Number of subjects: 20
Study 12432015 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 20
Study 12432015 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 10079415 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training (80% of maximum)
Number of subjects: 38
Study 10079415 — intervention group
Group type: COMPARATOR
Intervention: Flexibility training
Number of subjects: 38
Study 7580639 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 125
Study 7580639 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 125
Study 1302542 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao Wei Yan Powder (XWYP), 5-7g taken orally three times a day (tid) for 2-4 months.
Number of subjects: 242
Study 1302542 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control was).
Number of subjects: 242
Study 3927338 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0
Study 29947099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus saxagliptin
Number of subjects: 939